Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States

Key Points Question Is it cost-effective to implement population-wide genomic screening for hereditary breast and ovarian cancer (HBOC)? Findings This decision analytical model study found that genomic screening for HBOC among unselected women may be cost-effective depending on the age distribution of the women screened. Cascade testing of first-degree relatives added a modest improvement in clinical and economic value. Meaning Population-level genomic screening for HBOC targeting women aged 20 to 35 years could be considered in settings in which the outcomes of screening can be evaluated, particularly to avoid a reduction in mammography screening among patients with negative test results.

[1]  Dustin N. Hartzel,et al.  Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program , 2020, Journal of personalized medicine.

[2]  J. Cuzick,et al.  A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer , 2019, JAMA oncology.

[3]  M. Cabana,et al.  Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. , 2019, JAMA.

[4]  I. Winship,et al.  Response to Veenstra et al. , 2019, Genetics in Medicine.

[5]  Marc S. Williams,et al.  Cost-effectiveness of population genomic screening , 2019, Genetics in Medicine.

[6]  Angela Mariotto,et al.  Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. McNeil,et al.  Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis , 2019, Genetics in Medicine.

[8]  Sitao Wu,et al.  Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing , 2019, JAMA Oncology.

[9]  Matthew S. Lebo,et al.  Exome Sequencing–Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants , 2018, JAMA network open.

[10]  V. S. Gordeev,et al.  Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women , 2018, Journal of the National Cancer Institute.

[11]  D. Bowen,et al.  Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The Literature. , 2018, Health affairs.

[12]  Julie O. Culver,et al.  Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices , 2018, npj Genomic Medicine.

[13]  S. Vadaparampil,et al.  Racial disparities in BRCA testing and cancer risk management across a population‐based sample of young breast cancer survivors , 2017, Cancer.

[14]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[15]  Charles M Strom,et al.  A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  N. Rahman,et al.  A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  J. Ivanovich,et al.  Psychosocial and Clinical Factors Associated with Family Communication of Cancer Genetic Test Results among Women Diagnosed with Breast Cancer at a Young Age , 2017, Journal of Genetic Counseling.

[18]  Marylyn D. Ritchie,et al.  Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.

[19]  G. Sanders,et al.  Cost-Effectiveness in Health and Medicine , 2016 .

[20]  K. Armstrong,et al.  Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population? , 2016, Current Treatment Options in Oncology.

[21]  Oguzhan Alagoz,et al.  Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies , 2016, Annals of Internal Medicine.

[22]  S. Friedman,et al.  Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[23]  Jinbo Chen,et al.  Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers , 2014, Breast Cancer Research and Treatment.

[24]  M. King,et al.  Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. , 2014, JAMA.

[25]  M. King,et al.  Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2 , 2014, Proceedings of the National Academy of Sciences.

[26]  M. Leach,et al.  MRI breast screening in high-risk women: cancer detection and survival analysis , 2014, Breast Cancer Research and Treatment.

[27]  A. Neugut,et al.  Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers , 2011, Breast Cancer Research and Treatment.

[28]  J. Brazier,et al.  Health-state utility values in breast cancer , 2010, Expert review of pharmacoeconomics & outcomes research.

[29]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[30]  M. Robson,et al.  American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. , 2010, Journal of Clinical Oncology.

[31]  S. Kulasingam,et al.  Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. , 2009, Gynecologic oncology.

[32]  O. Olopade,et al.  Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. , 2006, The Lancet. Oncology.